2-phenyl-4-oxohydroquinoline has been researched along with paclitaxel in 1 studies
Studies (2-phenyl-4-oxohydroquinoline) | Trials (2-phenyl-4-oxohydroquinoline) | Recent Studies (post-2010) (2-phenyl-4-oxohydroquinoline) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
---|---|---|---|---|---|
26 | 0 | 8 | 31,874 | 5,729 | 15,395 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, YC; Guh, JH; Ho, YF; Huang, YC; Kuo, SC; Lin, TP; Lu, PH; Pan, SL; Teng, CM | 1 |
1 other study(ies) available for 2-phenyl-4-oxohydroquinoline and paclitaxel
Article | Year |
---|---|
Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; G2 Phase; Humans; Neoplasms; Paclitaxel; Quinolones; Tubulin; Tubulin Modulators; Vincristine | 2007 |